Valuation
- Market cap
- 4,234,000
- Revenue TTM
- $0
- Net income TTM
- $4,900,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 9,000
- Avg volume
- 29,138
- Day's range
- $0.04 – $0.04
- Shares out
- 109,126,000
- Stochastic %K
- 15%
- Beta
- 0.36
- Analysts
- —
- Price target
- $4.80
Company profile
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA t...
Show more
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was formerly known as LianBio and changed its name to LianMedical in July 2026. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 609 486 2308
- Website
- https://www.lian-medical.com/#/
- Address
- 103 Carnegie Center Drive, Suite 309, Princeton, United States
Latest news
No headlines yet.
